Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H-100 in Peyronie's disease
NCT02072018Phase 1Completed
- Sponsor
- Hybrid Medical
- Start
- Jun 2013
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Peyronie's disease comparing H-100 Arm with Placebo to H-100 Arm (2 arms). Primary endpoint: Safety measure at 6 months. Started Jun 2013; status: completed.
02
Drugs
H100
03
Conditions
Peyronie's disease
Beyond the preview
Go deeper on NCT02072018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02072018.